<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">18985146</article-id><article-id pub-id-type="pmc">2391294</article-id><article-id pub-id-type="publisher-id">08-PONE-RA-03948R1</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0002350</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Mental Health</subject><subject>Mental Health/Mood Disorders</subject><subject>Mental Health/Neuropsychiatric Disorders</subject><subject>Mental Health/Psychology</subject><subject>Mental Health/Sleep Disorders</subject></subj-group></article-categories><title-group><article-title>Elevated Stress-Hemoconcentration in Major Depression Is Normalized
by Antidepressant Treatment: Secondary Analysis from a Randomized, Double-Blind
Clinical Trial and Relevance to Cardiovascular Disease Risk</article-title><alt-title alt-title-type="running-head">Stress in Major Depression</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wong</surname><given-names>Ma-Li</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>&#x0002a;</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Dong</surname><given-names>Chuanhui</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Esposito</surname><given-names>Karin</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Thakur</surname><given-names>Sarika</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Weiqing</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Elashoff</surname><given-names>Robert M.</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Licinio</surname><given-names>Julio</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>
<addr-line>Department of Psychiatry and Behavioral Sciences, Leonard M. Miller
School of Medicine at the University of Miami, Miami, Florida, United States of
America</addr-line>
</aff><aff id="aff2">
<label>2</label>
<addr-line>Department of Psychiatry and Biobehavioral Sciences, David Geffen School
of Medicine at University of California Los Angeles, Los Angeles, California,
United States of America</addr-line>
</aff><aff id="aff3">
<label>3</label>
<addr-line>Department of Biomathematics, University of California Los Angeles, Los
Angeles, California, United States of America</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Baune</surname><given-names>Bernhard</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">James Cook University, Australia</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>mali@miami.edu</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: JL MW. Analyzed the data: JL ST RE MW
CD KE WL. Contributed reagents/materials/analysis tools: JL MW. Wrote the
paper: JL MW CD KE. Other: Approved the final version: JL RE WL ST KE CD
MW.</p></fn></author-notes><pub-date pub-type="collection"><year>2008</year></pub-date><pub-date pub-type="epub"><day>16</day><month>7</month><year>2008</year></pub-date><volume>3</volume><issue>7</issue><elocation-id>e2350</elocation-id><history><date date-type="received"><day>10</day><month>3</month><year>2008</year></date><date date-type="accepted"><day>16</day><month>4</month><year>2008</year></date></history><permissions><copyright-statement>Wong et al.</copyright-statement><copyright-year>2008</copyright-year><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><abstract><sec><title>Background</title><p>Major depressive disorder (MDD) is an independent risk factor for
cardiovascular disease (CVD); the presence of MDD symptoms in patients with
CVD is associated with a higher incidence of cardiac complications following
acute myocardial infarction (MI). Stress-hemoconcentration, a result of
psychological stress that might be a risk factor for the pathogenesis of
CVD, has been studied in stress-challenge paradigms but has not been
systematically studied in MDD.</p></sec><sec><title>Methods</title><p>Secondary analysis of stress hemoconcentration was performed on data from
controls and subjects with mild to moderate MDD participating in an ongoing
pharmacogenetic study of antidepressant treatment response to desipramine or
fluoxetine. Hematologic and hemorheologic measures of
stress-hemoconcentration included blood cell counts, hematocrit, hemoglobin,
total serum protein, and albumin, and whole blood viscosity.</p></sec><sec><title>Findings</title><p>Subjects with mild to moderate MDD had significantly increased hemorheologic
measures of stress-hemoconcentration and blood viscosity when compared to
controls; these measures were correlated with depression severity. Measures
of stress-hemoconcentration improved significantly after 8 weeks of
antidepressant treatment. Improvements in white blood cell count, red blood
cell measures and plasma volume were correlated with decreased severity of
depression.</p></sec><sec><title>Conclusions</title><p>Our secondary data analyses support that stress-hemoconcentration, possibly
caused by decrements in plasma volume during psychological stress, is
present in Mexican-American subjects with mild to moderate MDD at
non-challenged baseline conditions. We also found that after antidepressant
treatment hemorheologic measures of stress-hemoconcentration are improved
and are correlated with improvement of depressive symptoms. These findings
suggest that antidepressant treatment may have a positive impact in CVD by
ameliorating increased blood viscosity. Physicians should be aware of the
potential impact of measures of hemoconcentration and consider the
implications for cardiovascular risk in depressed patients.</p></sec></abstract><counts><page-count count="6"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Cardiovascular disease (CVD) risk has been linked to several emotional and
psychological factors, including stress and depression. Mental stress can elicit
acute coronary events and is considered a risk factor for CVD <xref rid="pone.0002350-Rozanski1" ref-type="bibr">[1]</xref>. Depressive symptoms,
which are common among patients with ischemic heart disease and those recovering
from an acute myocardial infarction (MI) <xref rid="pone.0002350-Cassem1" ref-type="bibr">[2]</xref>, <xref rid="pone.0002350-Carney1" ref-type="bibr">[3]</xref> are associated with an
increased risk of CVD, MI, and cardiac mortality <xref rid="pone.0002350-Carney1" ref-type="bibr">[3]</xref>&#x02013;<xref rid="pone.0002350-Bremmer1" ref-type="bibr">[7]</xref> In
patients with CVD, the presence of major depressive disorder (MDD) is associated
with higher rates of cardiac complications (such as reinfarction and the need for
revascularization) <xref rid="pone.0002350-Carney1" ref-type="bibr">[3]</xref> and a two-to-four times increased risk of cardiac
mortality compared with non-depressed patients <xref rid="pone.0002350-Ladwig1" ref-type="bibr">[4]</xref>&#x02013;<xref rid="pone.0002350-Barth1" ref-type="bibr">[6]</xref>.
Recently, the INTERHEART study reported an increase risk of acute MI across a
variety of psychosocial stressors, including depression, in a large, multinational,
case-control study <xref rid="pone.0002350-Rosengren1" ref-type="bibr">[8]</xref>. Given that the World Health Organization Global
Burden of Disease Survey estimates that by the year 2020, coronary heart disease and
depression will be the first and second most disabling conditions worldwide,
respectively, understanding the relationships between these disorders is critical
<xref rid="pone.0002350-Murray1" ref-type="bibr">[9]</xref>.</p><p>A number of mechanisms underlying the link between stress, depression and
cardiovascular disease have been proposed (for a comprehensive review, see reference
<xref rid="pone.0002350-Holmes1" ref-type="bibr">[10]</xref>).
Stress-related changes in sympathetically mediated hemorheologic factors related to
blood viscosity and hemoconcentration, such as hematocrit and total plasma protein,
may provide a link between behavioral stress and the development of CVD <xref rid="pone.0002350-Patterson1" ref-type="bibr">[11]</xref>.
Increased blood viscosity has been associated with cardiac ischemia, myocardial
infarction and necrosis, and stroke <xref rid="pone.0002350-Dintenfass1" ref-type="bibr">[12]</xref>&#x02013;<xref rid="pone.0002350-Lowe1" ref-type="bibr">[14]</xref>.
Hemoconcentration increases the risk of ischemia and thrombosis <xref rid="pone.0002350-Burge1" ref-type="bibr">[15]</xref>, <xref rid="pone.0002350-Isbister1" ref-type="bibr">[16]</xref>, and
increased levels of hematocrit and hemoglobin have been identified as independent
risk factors for CVD <xref rid="pone.0002350-Sorlie1" ref-type="bibr">[17]</xref>.</p><p>Behavioral/emotional stress and chronic anxiety have been shown to cause changes in
hemorheologic measures, possibly due to increases in catecholamines and blood
pressure <xref rid="pone.0002350-Allen1" ref-type="bibr">[18]</xref>. These changes have been referred to variably as
stress-hemoconcentration, stress polycythemia, relative polycythemia,
pseudopolycythemia, or spurious polycythemia and are characterized by an increased
red-cell-mass-to-plasma ratio resulting from a reduction in plasma volume in the
presence of normal red cell counts. Shifts of fluids out of the blood and into other
compartments of the body are responsible for this manifestation of hemoconcentration
<xref rid="pone.0002350-Allen1" ref-type="bibr">[18]</xref>.
Several studies have documented hemoconcentration in response to acute mental or
psychomotor challenges. Maes <italic>et al.</italic> studied students under two
baseline conditions, a few weeks before and after a difficult exam, and the day
before the stressor, and reported significant stress-induced hematological changes
<xref rid="pone.0002350-Maes1" ref-type="bibr">[19]</xref>.
Others have looked at more acute stress tasks (3&#x02013;20 minutes) in the
laboratory and report changes consistent with hemoconcentration <xref rid="pone.0002350-Muldoon1" ref-type="bibr">[20]</xref>&#x02013;<xref rid="pone.0002350-Patterson2" ref-type="bibr">[22]</xref>. Such findings have
implications for cardiovascular disease risk in acute and chronic stress.</p><p>Despite the importance of the hemorheologic changes described in
stress-hemoconcentration and the overlap between stress and depression in studies of
cardiovascular disease risk, such changes have not been systematically studied in
MDD. The present study is a secondary analysis of data from a randomized,
double-blind trial of fluoxetine versus desipramine in a group of outpatients with
mild to moderate MDD before and after antidepressant treatment compared to a group
of ethnically-matched controls. The primary analysis focused on genetic markers of
depression and antidepressant treatment response and has been reported elsewhere
<xref rid="pone.0002350-Wong1" ref-type="bibr">[23]</xref> Our
hypothesis for the secondary analysis presented in this paper was that subjects with
MDD would exhibit hematological and hemorheologic measures compatible with
stress-hemoconcentration, and that these measures would improve with successful
antidepressant treatment.</p></sec><sec id="s2"><title>Methods</title><sec id="s2a"><title>Study population</title><p>This study was approved by the University of California, Los Angeles (UCLA) and
University of Miami (UM) IRBs and has been registered in the public database
clinicaltrials.gov (NCT00265291). The study population consisted of control and
MDD individuals. All subjects gave written informed consent and received
comprehensive psychiatric and medical assessment. We used diagnostic and ratings
instruments that have been fully validated in English and in Spanish, and
conducted all assessments in the subject's primary language.</p><p>We studied 146 outpatient depressed subjects, all of whom were Mexican-Americans
(defined as having at least 3 grandparents born in Mexico) aged 19&#x02013;65
years, who were participating in an ongoing randomized, double-blind
pharmacogenetic study of antidepressant response to desipramine or fluoxetine
and completed the 8-week treatment trial (see <xref ref-type="table" rid="pone-0002350-t001">Table 1</xref> for population characteristics). All
depressed subjects had a current episode of unipolar major depression as
diagnosed by the Structured Clinical Interview for DSM-IV (SCID). Severity of
depression was assessed with the 21-Item Hamilton Depression Rating Scale
(HAM-D21) <xref rid="pone.0002350-Hamilton1" ref-type="bibr">[24]</xref>; a score of 18 or greater, with item number 1
(depressed mood) rated 2 or greater, was required for inclusion. The SCID and
HAM-D21 have been validated in English and Spanish, and all assessments were
conducted in the subject's primary language. Exclusion criteria
included any primary Axis I disorder other than MDD (e.g. dementia, psychotic
illness, bipolar disorder, adjustment disorder); electroconvulsive therapy in
the last 6 months; previous lack of response to desipramine or fluoxetine;
current, active suicidal ideation with a plan and strong intent; or any other
antidepressant treatment within the 2 weeks prior to enrollment. Patients
enrolled in this protocol were either drug-na&#x000ef;ve or drug-free for at
least two weeks; in that case, their antidepressant medication had been
discontinued for clinical reasons or because of non-adherence. Subjects with any
active medical illnesses that could be etiologically related to the ongoing
depressive episode (e.g. untreated hypothyroidism, cardiovascular accident
within the past 6 months, uncontrolled hypertension or diabetes), and who were
pregnant, lactating, currently using medications with significant central
nervous system activity (e.g. benzodiazepines), exhibiting illicit drug use
and/or alcohol abuse in the last 3 months, or currently enrolled in
psychotherapy were also excluded. Female patients were required to use
contraception during our treatment trial, but only 4 used hormonal contraceptive
agents. Our patients were predominantly non-smokers (only 6 were smokers), and
37 patients were taking other medications during our trial.</p><table-wrap id="pone-0002350-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0002350.t001</object-id><label>Table 1</label><caption><title>Demographic Data and BMI for Controls and MDD Subjects</title></caption><alternatives><graphic id="pone-0002350-t001-1" xlink:href="pone.0002350.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Subject<xref ref-type="table-fn" rid="nt101">&#x0002a;</xref>
</td><td align="left" rowspan="1" colspan="1">Gender<xref ref-type="table-fn" rid="nt102">&#x02020;</xref>
</td><td align="left" rowspan="1" colspan="1">N (&#x00025;)</td><td align="left" rowspan="1" colspan="1">Variable<xref ref-type="table-fn" rid="nt103">&#x02021;</xref>
</td><td align="left" rowspan="1" colspan="1">Mean&#x000b1;SD</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Controls</td><td align="left" rowspan="1" colspan="1">Female</td><td align="left" rowspan="1" colspan="1">33 (72)</td><td align="left" rowspan="1" colspan="1">Age</td><td align="left" rowspan="1" colspan="1">35.9&#x000b1;8.9</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">BMI</td><td align="left" rowspan="1" colspan="1">28.6&#x000b1;4.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">13 (28)</td><td align="left" rowspan="1" colspan="1">Age</td><td align="left" rowspan="1" colspan="1">33.2&#x000b1;7.7</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">BMI</td><td align="left" rowspan="1" colspan="1">29.4&#x000b1;4.6</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">All</td><td align="left" rowspan="1" colspan="1">46</td><td align="left" rowspan="1" colspan="1">Age</td><td align="left" rowspan="1" colspan="1">35.2&#x000b1;8.6</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">BMI</td><td align="left" rowspan="1" colspan="1">28.8&#x000b1;4.5</td></tr><tr><td align="left" rowspan="1" colspan="1">MDD Subjects</td><td align="left" rowspan="1" colspan="1">Female</td><td align="left" rowspan="1" colspan="1">97 (66)</td><td align="left" rowspan="1" colspan="1">Age</td><td align="left" rowspan="1" colspan="1">36.4&#x000b1;9.7</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">BMI</td><td align="left" rowspan="1" colspan="1">28.3&#x000b1;5.6</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">49 (34)</td><td align="left" rowspan="1" colspan="1">Age</td><td align="left" rowspan="1" colspan="1">38.9&#x000b1;9.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">BMI</td><td align="left" rowspan="1" colspan="1">28.2&#x000b1;4.0</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">All</td><td align="left" rowspan="1" colspan="1">146</td><td align="left" rowspan="1" colspan="1">Age</td><td align="left" rowspan="1" colspan="1">37.2&#x000b1;9.7</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">BMI</td><td align="left" rowspan="1" colspan="1">28.3&#x000b1;5.1</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><label>&#x0002a;</label><p>p for unpaired t-test is 0.194 for age and 0.543 for BMI between
controls and MDD patients.</p></fn><fn id="nt102"><label>&#x02020;</label><p>p for Chi-square test is 0.503 for gender ratio between controls and
MDD patients.</p></fn><fn id="nt103"><label>&#x02021;</label><p>Age in year; BMI: body mass index defined as weight in kilogram
divided by the square of height in meters.</p></fn></table-wrap-foot></table-wrap><p>We studied 46 ethnically-matched control subjects (<xref ref-type="table" rid="pone-0002350-t001">Table 1</xref>) who were recruited from the same
Mexican-American Los Angeles community and evaluated by the same bilingual,
clinical research team at the Center for Pharmacogenomics and Clinical
Pharmacology, David Geffen School of Medicine at UCLA <xref rid="pone.0002350-Licinio1" ref-type="bibr">[25]</xref>. Control subjects
were in good general health and free of ongoing physical illness. They showed no
evidence of major psychiatric illness in clinical and structured interview.
Control and MDD individuals received the same comprehensive psychiatric and
medical assessments.</p></sec><sec id="s2b"><title>Antidepressant treatment</title><p>All MDD subjects reported here completed 8 weeks of a randomized, double-blind
trial of antidepressant treatment response to desipramine or fluoxetine as part
of a pharmacogenetic study. The treatment had two phases. Phase 1 was a 1-week,
single-blind placebo lead-in phase to eliminate placebo responders. Subjects who
continued to meet the inclusion criteria after Phase 1 were randomly assigned to
one of two treatment groups in a double-blind manner in Phase 2 during which
they received fluoxetine 10&#x02013;40 mg/day or desipramine 50&#x02013;200
mg/day, for 8 weeks, with a dose escalation based on clinical outcomes. All
subjects had 9 weeks of structured follow-up assessments. Our primary clinical
outcome measure within the depressed group receiving antidepressant treatment
was the HAM-D21. Remitter was defined as the patients who had a final HAM-D21
score &#x0003c;8.</p></sec><sec id="s2c"><title>Hemorheologic measures</title><p>Blood was collected from a vein in the antecubital fossa before beginning
antidepressant treatment (week &#x02212;2) and at the end of treatment (week
8). All samples were drawn after the subjects had rested in a supine position
for 5&#x02013;10 minutes. Samples for white blood cell (WBC) and red blood
cell (RBC) count, hematocrit (HCT) and hemoglobin (HGB) levels were drawn into 7
ml ethylenediaminetetraacetic acid (K<sub>2</sub> EDTA)
BD-Vacutainer<sup>&#x000ae;</sup> tubes. Total serum protein (TSP) and
albumin samples were drawn into chilled 7-ml K<sub>2</sub> EDTA-treated
BD-Vacutainer<sup>&#x000ae;</sup> tubes and placed on ice until centrifuged
at 3000 rpm for 10 minutes at 4&#x000b0;C. Blood count and protein analysis were
performed by the UCLA Clinical Laboratories and Pathology Services using a
Sysmex XE-2100 (Sysmex Co, Kobe, Japan) and Synchron LX<sup>&#x000ae;</sup>20
(Beckman Coulter, Fullerton, CA), respectively.</p></sec><sec id="s2d"><title>Whole Blood Viscosity (WBV) Estimation</title><p>WBV was determined in centipoises (cP) at a shear rate of 208
seconds<sup>&#x02212;1</sup> using the following equation:
WBV&#x0200a;=&#x0200a;0.12&#x000d7;HCT
(&#x00025;)&#x0002b;0.17&#x000d7;serum proteins (g/dL)</p><p>This equation has been validated by de Simone <italic>et al</italic>
<xref rid="pone.0002350-deSimone1" ref-type="bibr">[26]</xref>. By comparison with direct WBV measurements
(<italic>r</italic>&#x0200a;=&#x0200a;0.92,
n&#x0200a;=&#x0200a;50) in adults.</p></sec><sec id="s2e"><title>Plasma Volume Estimation</title><p>Estimates in plasma volume changes before and after 8-weeks antidepressant
treatment was calculated using the following formula:<disp-formula><graphic xlink:href="pone.0002350.e001.jpg" mimetype="image" position="float"/></disp-formula>where PvolT is the plasma volume after antidepressant treatment,
HgbB is the hemoglobin before treatment (at &#x02212;2 week), HgbA and HctA
are the hemoglobin and hematocrit after 8-week treatment, respectively <xref rid="pone.0002350-Dill1" ref-type="bibr">[27]</xref>.</p></sec><sec id="s2f"><title>Statistical Analyses</title><p>Variables used for secondary data analyses included HAM-D21 scores and the
following measurements: RBC, HGB, HCT, WBC, TSP, albumin levels and estimation
of WBV. MDD subjects were analyzed before (week &#x02212;2) and after
treatment (week 8), and control subjects were measured at one time point for
comparison.</p><p>To assess similarity between depressed and control subjects, unpaired t-tests
were used to compare age and BMI means and a &#x003c7;<sup>2</sup> test was used to
compare gender ratios. To examine the potential effects of gender and age,
unpaired t-tests were also performed for the difference in blood measurements
between female and male, and Pearson correlation analysis was conducted for the
correlation of age with blood measurements. To adjust for gender and age, a
general linear model (GLM) was employed to conduct multivariate tests (MANOVA)
to compare blood measurements between MDD subjects and controls or between
desipramine- and fluoxetine- treated MDD subjects. Paired T-tests were used to
compare blood measurements before and after treatment in MDD subjects. Spearman
partial correlation was used to measure the degree of association of HAM-D21
score with the blood measurements by controlling for age and gender. Stepwise
logistic regression analysis was conducted to screen the predictors that allow a
differentiation between remitter and non-remitter patients using the baseline
HAM-D21 score, baseline blood measurements, antidepressant medication, age, and
gender variables.</p><p>All analyses were performed using SPSS version 14.0 (SPSS Inc., Chicago, IL,
USA), except for Spearman partial correlation analysis which was conducted with
SAS version 9.1 (SAS Institute Inc., Cary, NC, USA). As HAM-D21 score is an
ordinal measurement rated on a 5-point scale for each item (from &#x0201c;0
&#x02013; not present&#x0201d; to &#x0201c;4 &#x02013;
severe&#x0201d;) and did not follow normal distribution when used as an
interval variable, Spearman partial correlation was used. A significance level
of 0.05 was used for all statistical testing, and the Bonferroni post-hoc method
of correction was used to correct for multiple testing.</p></sec><sec id="s2g"><title>Role of Funding Sources:</title><p>This study was funded by the National Institute of General Medical Sciences
(NIGMS), the National Institute of Diabetes and Digestive and Kidney Diseases
(NIDDK), and the National Center for Research Resources (NCRR). The sponsors
were not involved in the study design; the collection analysis and
interpretation of data; the writing of the report; or the decision to
publish.</p></sec></sec><sec id="s3"><title>Results</title><sec id="s3a"><title>Hemorheologic and Hematological Measures in MDD Subjects and Controls</title><p>Our data are compatible with classical findings that gender influences red blood
cell (RBC) measurements and albumin levels. RBC measurements are correlated with
gender; female subjects had lower RBC count (<italic>p</italic>&#x0003c;0.0001;
4.5&#x000b1;0.3&#x000d7;10<sup>6</sup>/ &#x000b5;L in females vs
5.1&#x000b1;0.4&#x000d7;10<sup>6</sup>/ &#x000b5;L in males), lower
HGB levels (<italic>p</italic>&#x0003c;0.0001; 13.2&#x000b1;1.1 g/dL in
females vs 15.3&#x000b1;1.0 g/dL in males) and lower albumin levels
(<italic>p</italic>&#x0200a;=&#x0200a;0.0004;
4.1&#x000b1;0.3 g/dL in females vs 4.3 g/dL&#x000b1;0.3 g/dL in males).
The results of correlation analysis showed that age was conversely correlated
with TSP (r&#x0200a;=&#x0200a;&#x02212;0.17,
<italic>p</italic>&#x0200a;=&#x0200a;0.019) and albumin
(r&#x0200a;=&#x0200a;&#x02212;0.18,
<italic>p</italic>&#x0200a;=&#x0200a;0.012).</p><p>Therefore, we performed multivariate analysis of variance (MANOVA) to compare
group differences in hemorheologic measures and WBC count by controlling for
gender and age (<xref ref-type="table" rid="pone-0002350-t002">Table 2</xref>).
Our results showed that before treatment, MDD subjects had significantly
increased hemorheologic measures in total RBC count
(<italic>p</italic>&#x0200a;=&#x0200a;0.048), HBG
(<italic>p</italic>&#x0200a;=&#x0200a;0.005), HCT
(<italic>p</italic>&#x0200a;=&#x0200a;0.001), TSP
concentrations (<italic>p</italic>&#x0200a;=&#x0200a;0.010),
and total WBC count
(<italic>p</italic>&#x0200a;=&#x0200a;0.039). Albumin levels
showed a trend towards an increase when compared to controls
(<italic>p</italic>&#x0200a;=&#x0200a;0.052). MDD subjects also
had higher estimated WBV than controls (<italic>p</italic>&#x0003c;0.001). After
treatment, no significant differences in the hemorheologic measures or WBC count
were found between MDD subjects and controls (all <italic>p</italic>
values&#x02265;0.088).</p><table-wrap id="pone-0002350-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0002350.t002</object-id><label>Table 2</label><caption><title>Hemorheologic Measures and WBC Count in MDD Subjects before Treatment
(week &#x02212;2) and Controls</title></caption><alternatives><graphic id="pone-0002350-t002-2" xlink:href="pone.0002350.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Hemorheologic Measures</td><td align="left" rowspan="1" colspan="1">Controls
(N&#x0200a;=&#x0200a;46)<xref ref-type="table-fn" rid="nt104">&#x0002a;</xref>
</td><td align="left" rowspan="1" colspan="1">MDD Subjects
(N&#x0200a;=&#x0200a;146)<xref ref-type="table-fn" rid="nt104">&#x0002a;</xref>
</td><td align="left" rowspan="1" colspan="1">
<italic>p</italic>
<xref ref-type="table-fn" rid="nt105">&#x02020;</xref>
</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">RBC count &#x02212;10<sup>6</sup>/&#x000b5;L</td><td align="left" rowspan="1" colspan="1">4.6&#x000b1;0.5</td><td align="left" rowspan="1" colspan="1">4.7&#x000b1;0.4</td><td align="left" rowspan="1" colspan="1">
<bold>0.048</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">HGB &#x02013; g/dL</td><td align="left" rowspan="1" colspan="1">13.4&#x000b1;1.6</td><td align="left" rowspan="1" colspan="1">14.0&#x000b1;1.4</td><td align="left" rowspan="1" colspan="1">
<bold>0.005</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">HCT &#x02212;&#x00025;</td><td align="left" rowspan="1" colspan="1">39.5&#x000b1;4.2</td><td align="left" rowspan="1" colspan="1">41.4&#x000b1;3.5</td><td align="left" rowspan="1" colspan="1">
<bold>0.001</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">TSP &#x02013; g/dL</td><td align="left" rowspan="1" colspan="1">7.1&#x000b1;0.5</td><td align="left" rowspan="1" colspan="1">7.3&#x000b1;0.5</td><td align="left" rowspan="1" colspan="1">
<bold>0.010</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Albumin &#x02013; g/dL</td><td align="left" rowspan="1" colspan="1">4.1&#x000b1;0.4</td><td align="left" rowspan="1" colspan="1">4.2&#x000b1;0.3</td><td align="left" rowspan="1" colspan="1">0.052</td></tr><tr><td align="left" rowspan="1" colspan="1">WBV &#x02013; cP</td><td align="left" rowspan="1" colspan="1">5.9&#x000b1;0.5</td><td align="left" rowspan="1" colspan="1">6.2&#x000b1;0.4</td><td align="left" rowspan="1" colspan="1">
<bold>&#x0003c;0.001</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">WBC count &#x02212;10<sup>6</sup>/&#x000b5;L</td><td align="left" rowspan="1" colspan="1">6.8&#x000b1;1.5</td><td align="left" rowspan="1" colspan="1">7.5&#x000b1;2.1</td><td align="left" rowspan="1" colspan="1">0.052</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt104"><label>&#x0002a;</label><p>Values are means&#x000b1;SD.</p></fn><fn id="nt105"><label>&#x02020;</label><p>p was based on MANOVA using GLM model by adjusting for age and
gender.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3b"><title>Hemorheologic Measures in MDD Subjects Before and After Antidepressant
Treatment</title><p>In MDD subjects, hemorheologic parameters of stress-hemoconcentration improved
after 8 weeks of antidepressant treatment (<xref ref-type="table" rid="pone-0002350-t003">Table 3</xref>). Paired t-test analyses showed that
all the six hemorheologic measures and the WBC count in MDD subjects decreased
significantly after antidepressant treatment (<italic>p</italic>&#x02264;0.0003).</p><table-wrap id="pone-0002350-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0002350.t003</object-id><label>Table 3</label><caption><title>Hemorheologic Measures and WBC Count in MDD Subjects before (week
&#x02212;2) and after (week 8) Treatment</title></caption><alternatives><graphic id="pone-0002350-t003-3" xlink:href="pone.0002350.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Hemorheologic Measures</td><td align="left" rowspan="1" colspan="1">Number of Patients<xref ref-type="table-fn" rid="nt106">&#x0002a;</xref>
</td><td align="left" rowspan="1" colspan="1">Before Treatment<xref ref-type="table-fn" rid="nt107">#</xref>
</td><td align="left" rowspan="1" colspan="1">After Treatment<xref ref-type="table-fn" rid="nt107">#</xref>
</td><td align="left" rowspan="1" colspan="1">
<italic>p</italic>
<xref ref-type="table-fn" rid="nt108">&#x02020;</xref>
</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">RBC count &#x02212;10<sup>6</sup>/&#x000b5;L</td><td align="left" rowspan="1" colspan="1">146</td><td align="left" rowspan="1" colspan="1">4.7&#x000b1;0.4</td><td align="left" rowspan="1" colspan="1">4.6&#x000b1;0.4</td><td align="left" rowspan="1" colspan="1">
<bold>0.0003</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">HGB &#x02013; g/dL</td><td align="left" rowspan="1" colspan="1">146</td><td align="left" rowspan="1" colspan="1">14.0&#x000b1;1.4</td><td align="left" rowspan="1" colspan="1">13.8&#x000b1;1.4</td><td align="left" rowspan="1" colspan="1">
<bold>&#x0003c;0.0001</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">HCT &#x02212;&#x00025;</td><td align="left" rowspan="1" colspan="1">146</td><td align="left" rowspan="1" colspan="1">41.4&#x000b1;3.5</td><td align="left" rowspan="1" colspan="1">40.6&#x000b1;3.6</td><td align="left" rowspan="1" colspan="1">
<bold>&#x0003c;0.0001</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">TSP &#x02013; g/dL</td><td align="left" rowspan="1" colspan="1">146</td><td align="left" rowspan="1" colspan="1">7.3&#x000b1;0.5</td><td align="left" rowspan="1" colspan="1">7.1&#x000b1;0.4</td><td align="left" rowspan="1" colspan="1">
<bold>&#x0003c;0.0001</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Albumin &#x02013; g/dL</td><td align="left" rowspan="1" colspan="1">146</td><td align="left" rowspan="1" colspan="1">4.2&#x000b1;0.3</td><td align="left" rowspan="1" colspan="1">4.0&#x000b1;0.3</td><td align="left" rowspan="1" colspan="1">
<bold>&#x0003c;0.0001</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">WBV &#x02013; cP</td><td align="left" rowspan="1" colspan="1">146</td><td align="left" rowspan="1" colspan="1">6.2&#x000b1;0.4</td><td align="left" rowspan="1" colspan="1">6.1&#x000b1;0.5</td><td align="left" rowspan="1" colspan="1">
<bold>&#x0003c;0.0001</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">WBC count &#x02212;10<sup>6</sup>/&#x000b5;L</td><td align="left" rowspan="1" colspan="1">146</td><td align="left" rowspan="1" colspan="1">7.5&#x000b1;2.1</td><td align="left" rowspan="1" colspan="1">6.7&#x000b1;1.7</td><td align="left" rowspan="1" colspan="1">
<bold>&#x0003c;0.0001</bold>
</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt106"><label>&#x0002a;</label><p>Subjects with no missing data.</p></fn><fn id="nt107"><label>#</label><p>Values are means&#x000b1;SD.</p></fn><fn id="nt108"><label>&#x02020;</label><p>p was based on paired t-test.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3c"><title>Hemorheologic Measures in Desipramine- and Fluoxetine- Treated MDD Subjects</title><p>Measures of stress-hemoconcentration were not significantly different in subjects
treated with desipramine or fluoxetine in MANOVA analysis. Our analyses showed
that total RBC count, HBG, HCT, total WBC, TSP and albumin did not differ
between the two groups in the final week of treatment.</p></sec><sec id="s3d"><title>Hemorheologic Measures and HAM-D21 Score in MDD Subjects</title><p>
<xref ref-type="table" rid="pone-0002350-t004">Table 4</xref> presents the
results of Spearman partial correlation analyses by controlling for age and
gender. Our data showed that before treatment, hemorheologic measures were
correlated with HAM-D21 score with a correlation coefficient of 0.21 for WBC
count (<italic>p</italic>&#x0200a;=&#x0200a;0.01), 0.18 for RBC
count (<italic>p</italic>&#x0200a;=&#x0200a;0.027), 0.24 for
HCT (<italic>p</italic>&#x0200a;=&#x0200a;0.003), 0.29 for WBV
(<italic>p</italic>&#x0003c;0.001), and 0.22 for albumin level
(<italic>p</italic>&#x0200a;=&#x0200a;0.009). Our data also
showed that improvements in WBC count, RBC measures, and plasma volume
percentage were positively correlated with the improvement in HAM-D21 score,
although no statistical significant difference was found for the change in
hemorheologic measures between remitters and non-remitters.</p><table-wrap id="pone-0002350-t004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0002350.t004</object-id><label>Table 4</label><caption><title>Correlations of HAM-D21 Score, Hemorheologic Measures and WBC Count
in MDD Subjects (N&#x0200a;=&#x0200a;146)</title></caption><alternatives><graphic id="pone-0002350-t004-4" xlink:href="pone.0002350.t004"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Hemorheologic Measures before Treatment</td><td colspan="2" align="left" rowspan="1">HAM-D21 Score before Treatment</td><td align="left" rowspan="1" colspan="1">Change in Hemorheologic Measures with treatment</td><td colspan="2" align="left" rowspan="1">Change in HAM-D21 Score</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<italic>r</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>p</italic>
<xref ref-type="table-fn" rid="nt109">&#x02020;</xref>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<italic>r</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>p</italic>
<xref ref-type="table-fn" rid="nt109">&#x02020;</xref>
</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">RBC count &#x02212;10<sup>6</sup>/&#x000b5;L</td><td align="left" rowspan="1" colspan="1">0.18</td><td align="left" rowspan="1" colspan="1">
<bold>0.027</bold>
</td><td align="left" rowspan="1" colspan="1">RBC count &#x02212;10<sup>6</sup>/&#x000b5;L</td><td align="left" rowspan="1" colspan="1">0.22</td><td align="left" rowspan="1" colspan="1">
<bold>0.008</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">HGB &#x02013; g/dL</td><td align="left" rowspan="1" colspan="1">0.14</td><td align="left" rowspan="1" colspan="1">0.105</td><td align="left" rowspan="1" colspan="1">HGB &#x02013; g/dL</td><td align="left" rowspan="1" colspan="1">0.18</td><td align="left" rowspan="1" colspan="1">
<bold>0.027</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">HCT &#x02212;&#x00025;</td><td align="left" rowspan="1" colspan="1">0.24</td><td align="left" rowspan="1" colspan="1">
<bold>0.003</bold>
</td><td align="left" rowspan="1" colspan="1">HCT &#x02212;&#x00025;</td><td align="left" rowspan="1" colspan="1">0.22</td><td align="left" rowspan="1" colspan="1">
<bold>0.008</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">TSP &#x02013; g/dL</td><td align="left" rowspan="1" colspan="1">0.26</td><td align="left" rowspan="1" colspan="1">
<bold>0.002</bold>
</td><td align="left" rowspan="1" colspan="1">TSP &#x02013; g/dL</td><td align="left" rowspan="1" colspan="1">0.14</td><td align="left" rowspan="1" colspan="1">0.086</td></tr><tr><td align="left" rowspan="1" colspan="1">Albumin &#x02013; g/dL</td><td align="left" rowspan="1" colspan="1">0.22</td><td align="left" rowspan="1" colspan="1">
<bold>0.009</bold>
</td><td align="left" rowspan="1" colspan="1">Albumin &#x02013; g/dL</td><td align="left" rowspan="1" colspan="1">0.13</td><td align="left" rowspan="1" colspan="1">0.115</td></tr><tr><td align="left" rowspan="1" colspan="1">WBV &#x02013; cP</td><td align="left" rowspan="1" colspan="1">0.29</td><td align="left" rowspan="1" colspan="1">
<bold>&#x0003c;0.001</bold>
</td><td align="left" rowspan="1" colspan="1">WBV &#x02013; cP</td><td align="left" rowspan="1" colspan="1">0.21</td><td align="left" rowspan="1" colspan="1">
<bold>0.010</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Plasma volume<xref ref-type="table-fn" rid="nt110">&#x000b6;</xref>
</td><td align="left" rowspan="1" colspan="1">0.20</td><td align="left" rowspan="1" colspan="1">
<bold>0.017</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">WBC count &#x02212;10<sup>6</sup>/&#x000b5;L</td><td align="left" rowspan="1" colspan="1">0.21</td><td align="left" rowspan="1" colspan="1">0.010</td><td align="left" rowspan="1" colspan="1">WBC count &#x02212;10<sup>6</sup>/&#x000b5;L</td><td align="left" rowspan="1" colspan="1">0.23</td><td align="left" rowspan="1" colspan="1">0.007</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt109"><label>&#x02020;</label><p>p was based on Spearman partial correlation by controlling for age
and gender.</p></fn><fn id="nt110"><label>&#x000b6;</label><p>Plasma volume change &#x00025; after treatment based on the method
provided by Dill and Costill.<sup>27</sup>
</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3e"><title>Baseline Hemorheologic Measures and Clinical Remission Status</title><p>Stepwise logistic regression analysis revealed that the significant predictors of
remission included HAM-D21 score (OR&#x0200a;=&#x0200a;0.85,
95&#x00025;CI&#x0200a;=&#x0200a;0.77&#x02013;0.93,
<italic>p</italic>&#x0200a;=&#x0200a;0.0003), TSP
(OR&#x0200a;=&#x0200a;2.81,
95&#x00025;CI&#x0200a;=&#x0200a;1.03&#x02013;7.67,
<italic>p</italic>&#x0200a;=&#x0200a;0.044) and albumin
(OR&#x0200a;=&#x0200a;0.13,
95&#x00025;CI&#x0200a;=&#x0200a;0.02&#x02013;0.67,
<italic>p</italic>&#x0200a;=&#x0200a;0.015) at baseline.
Taking together, the model yielded a 73&#x00025; concordance between the
observed and predicted remission status.</p></sec></sec><sec id="s4"><title>Discussion</title><p>Our secondary data analyses indicate that hemorheologic measures of
stress-hemoconcentration are present in Mexican-American individuals with mild to
moderate MDD and that these measures decrease significantly after 8 weeks of
antidepressant treatment to levels which were the same as those of controls.
Measures we obtained in depressed subjects at rest (in the absence of any deliberate
psychological challenge) are comparable to those elicited after a stressful
challenge in other studies <xref rid="pone.0002350-Maes1" ref-type="bibr">[19]</xref>&#x02013;<xref rid="pone.0002350-Patterson2" ref-type="bibr">[22]</xref>. We propose that
stress-hemoconcentration may contribute to the increased risk of CVD found in MDD.</p><p>Psychological stress has been identified as a risk factor for CVD, as a trigger of
acute coronary events, and as a contributor to the pathogenesis of atherosclerosis
and hypertension <xref rid="pone.0002350-Holmes1" ref-type="bibr">[10]</xref>. Thus, given our findings of
stress-hemoconcentration at rest in MDD, this mechanism is also a potential link in
the association of MDD and CVD. In MDD, stress-hemoconcentration may increase blood
viscosity; this may lead to a decrease in pressure at vulnerable branching sites of
coronary arteries and increased exposure time to atherogenic substances <xref rid="pone.0002350-Allen1" ref-type="bibr">[18]</xref>.</p><p>During stress, hemoconcentration can be at least partially explained by sympathetic
nervous system activation (for a comprehensive review see reference <xref rid="pone.0002350-Patterson2" ref-type="bibr">[22]</xref>.
Infusion of catecholamines has been shown to result in reductions of plasma volume
with parallel rises in hematocrit, possibly due to increases in systemic pressure
and capillary hydrostatic pressure that reflects passive movement of fluid out of
the capillaries. Elevations in plasma catecholamines have also been described in MDD
<xref rid="pone.0002350-Gold1" ref-type="bibr">[28]</xref> and
thus, sympathetic nervous system activation would also be a valid explanation for
alterations of stress-hemoconcentration measures in MDD, but in this study we have
not obtained concomitant measures of plasma catecholamines; therefore, this possible
relationship remains to be directly documented.</p><p>Stress hemoconcentration has not been systematically studied in MDD. Several studies
on relatively small numbers of depressed subjects (30&#x02013;50) examining other
systemic aspects of depression &#x02013; inflammation and the acute phase response
&#x02013; have reported on some measures that overlap with those we examined.
Total serum protein <xref rid="pone.0002350-VanHunsel1" ref-type="bibr">[29]</xref>, albumin <xref rid="pone.0002350-Huang1" ref-type="bibr">[30]</xref>, as well as RBC, HGB and
HCT <xref rid="pone.0002350-Maes2" ref-type="bibr">[31]</xref>
have been reported as decreased in depression, unlike the increase we report in our
population. Several major differences exist between these studies and ours, the most
significant being that the studies were all conducted on smaller, acute inpatient
populations. Multiple factors may differentiate inpatients with depression from
outpatients: higher severity of illness, with the possibility of decreased mobility
and poor nutritional status, and greater duration of illness with more exposure to
medication. We examined several potential confounds in our study and found no
difference in our results if we eliminated individuals with history of
cardiovascular problems (n&#x0200a;=&#x0200a;8) or family history
of cardiac problems (n&#x0200a;=&#x0200a;17) or individuals taking
other medication (n&#x0200a;=&#x0200a;37) or using hormonal
contraceptive agents (n&#x0200a;=&#x0200a;4) or smoking
(n&#x0200a;=&#x0200a;6). One limitation of the current study is
that we did not directly measure fluid and food intake; another is that we did not
collect the information on smoking habits for all the patients and controls. No
significant weight change was observed over the course of the study, and while the
appetite item on the Beck Depression Inventory did show improvement, there was no
significant correlation between appetite score change and change in
hemoconcentration measures. A strength of our study is the focus on one ethnic group
with strict inclusion criteria (3 of 4 grandparents born in Mexico), thus minimizing
variation that could be introduced by a genetically more heterogenous population. It
is unknown whether other ethnic groups could react differently.</p><p>Importantly, the changes in hemorheologic measures that we report in our depressed
subjects improved with treatment. Treatment of depression has been reported to
lessen the risk of MI associated with depression <xref rid="pone.0002350-Ahrens1" ref-type="bibr">[32]</xref>, <xref rid="pone.0002350-Avery1" ref-type="bibr">[33]</xref>, and MDD patients
adequately treated have lower heart disease mortality than inadequately treated
depressed patients <xref rid="pone.0002350-Avery1" ref-type="bibr">[33]</xref>. The use of antidepressants remains controversial
in CVD, especially the use of tricyclic antidepressant medications because they
could be associated with an increase risk of CVD <xref rid="pone.0002350-Cohen1" ref-type="bibr">[34]</xref>. Roose <italic>et al.</italic>
<xref rid="pone.0002350-Roose1" ref-type="bibr">[35]</xref> have
reported in a small controlled trial that paroxetine and nortriptyline are effective
treatments for MDD patients with ischemic heart disease. A randomized clinical trial
showed that selective serotonin reuptake inhibitor (SSRI) sertraline was safe and
effective in treating recurrent depression in patients with an acute MI or unstable
angina and without other life-threatening medical conditions <xref rid="pone.0002350-Glassman1" ref-type="bibr">[36]</xref>. Emerging evidence
shows that treatment of MDD patients who experience an acute MI with SSRI
antidepressants might decrease mortality or cardiac events <xref rid="pone.0002350-Taylor1" ref-type="bibr">[37]</xref>. There is evidence that
lower adherence to prescribed medications and cardiac prevention measures is present
in post-MI patients with depression <xref rid="pone.0002350-Gehi1" ref-type="bibr">[38]</xref> and that treatment of MDD could improve
compliance with CVD treatment. In this study, we examined both a tricyclic and an
SSRI antidepressant. Our response rates, which were higher than in some other
antidepressant trials, may reflect the fact that placebo responders were eliminated
after the first week and that our patients were from a previously untreated,
community-based population. A potential concern was the possibility of orthostatic
hypotension with desipramine, and subjects in this treatment group did demonstrate
more orthostasis by pulse than those treated with fluoxetine (data not shown).
However, as described, all of our samples were taken after 5&#x02013;10 minutes of
supine rest. No difference was observed in treatment response or in hemorheologic
measures between the two drugs. <xref ref-type="fig" rid="pone-0002350-g001">Figure
1</xref> gives a brief overview on how we could integrate data on acute
stress-hemoconcentration and MDD.</p><fig id="pone-0002350-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0002350.g001</object-id><label>Figure 1</label><caption><title>Relationship between acute stress, stress-hemoconcentration and MDD.</title><p>Normal individuals can display hemorheologic measures of
stress-hemoconcentration after acute psychological stress. Those measures
return to baseline levels within minutes after the stress situation is
terminated. Subjects with major depressive disorder (MDD) display
stress-hemoconcentration at baseline, non-stressed conditions and those
measures return to baseline levels in responders to an 8-week treatment with
antidepressants.</p></caption><graphic xlink:href="pone.0002350.g001"/></fig><p>Our data based on secoondary analyses support the notion that successful
antidepressant treatment ameliorates hemorheologic measures of
stress-hemoconcentration, which indicates that factors consistent with increased
blood viscosity and the advancement of atherosclerotic plaque in low-pressure sites
in the arterial tree may be alleviated following the improvement of MDD
symptomatology. Our results suggest that hemorheologic changes in patients suffering
from MDD could contribute to an increased risk for CVD. Antidepressant treatment
reduces not only the psychological symptoms of depression, but it also may reduce
this potentially important depression-associated risk factor for CVD. Hemorheologic
measures of stress-hemoconcentration are of low cost and often contained in routine
lab assessments, but they have not yet been considered as a relevant biomarker of
CVD risk in depression. We suggest here that physicians who assess major depression
and provide antidepressant treatment should consider stress hemoconcentration when
evaluating the cardiovascular risk factors of depressed patients.</p></sec><sec sec-type="supplementary-material" id="s5"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0002350.s001"><label>Protocol S1</label><caption><p>Trial Protocol</p><p>(0.06 MB PDF)</p></caption><media xlink:href="pone.0002350.s001.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><fn-group><fn fn-type="COI-statement"><p><bold>Competing Interests: </bold>Julio Licinio has been a consultant for Eli Lilly, but Eli Lilly did not in any
way contribute to the design, analysis or writing of these data, and is not
aware of these results, which have not been presented to Eli Lilly.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>NIH grants GM61394, RR017365, MH062777, RR000865, RR16996, HG002500, and
DK063240, and Institutional Funds from the University of Miami, Department of
Psychiatry &#x00026; Behavioral Sciences</p></fn></fn-group><ref-list><title>References</title><ref id="pone.0002350-Rozanski1"><label>1</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rozanski</surname><given-names>A</given-names></name><name><surname>Bairey</surname><given-names>CN</given-names></name><name><surname>Krantz</surname><given-names>DS</given-names></name><name><surname>Friedman</surname><given-names>J</given-names></name><name><surname>Resser</surname><given-names>KJ</given-names></name><name><surname>Morell</surname><given-names>M</given-names></name><etal/></person-group>
<year>1988</year>
<article-title>Mental stress and the induction of silent myocardial ischemia in
patients with coronary artery disease.</article-title>
<source>N Engl J Med</source>
<volume>Apr 21; 318(16)</volume>
<fpage>1005</fpage>
<lpage>12</lpage>
</element-citation></ref><ref id="pone.0002350-Cassem1"><label>2</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cassem</surname><given-names>NH</given-names></name><name><surname>Hackett</surname><given-names>TP</given-names></name></person-group>
<year>1977</year>
<article-title>Psychological aspects of myocardial infarction.</article-title>
<source>The Medical clinics of North America</source>
<volume>Jul; 61(4)</volume>
<fpage>711</fpage>
<lpage>21</lpage>
</element-citation></ref><ref id="pone.0002350-Carney1"><label>3</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Carney</surname><given-names>RM</given-names></name><name><surname>Freedland</surname><given-names>KE</given-names></name><name><surname>Miller</surname><given-names>GE</given-names></name><name><surname>Jaffe</surname><given-names>AS</given-names></name></person-group>
<year>2002</year>
<article-title>Depression as a risk factor for cardiac mortality and morbidity:
a review of potential mechanisms.</article-title>
<source>Journal of psychosomatic research</source>
<volume>Oct; 53(4)</volume>
<fpage>897</fpage>
<lpage>902</lpage>
</element-citation></ref><ref id="pone.0002350-Ladwig1"><label>4</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ladwig</surname><given-names>KH</given-names></name><name><surname>Kieser</surname><given-names>M</given-names></name><name><surname>Konig</surname><given-names>J</given-names></name><name><surname>Breithardt</surname><given-names>G</given-names></name><name><surname>Borggrefe</surname><given-names>M</given-names></name></person-group>
<year>1991</year>
<article-title>Affective disorders and survival after acute myocardial
infarction. Results from the post-infarction late potential study.</article-title>
<source>European heart journal</source>
<volume>Sep; 12(9)</volume>
<fpage>959</fpage>
<lpage>64</lpage>
</element-citation></ref><ref id="pone.0002350-FrasureSmith1"><label>5</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Frasure-Smith</surname><given-names>N</given-names></name><name><surname>Lesperance</surname><given-names>F</given-names></name><name><surname>Talajic</surname><given-names>M</given-names></name></person-group>
<year>1995</year>
<article-title>Depression and 18-month prognosis after myocardial infarction.</article-title>
<source>Circulation</source>
<volume>Feb 15; 91(4)</volume>
<fpage>999</fpage>
<lpage>1005</lpage>
</element-citation></ref><ref id="pone.0002350-Barth1"><label>6</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barth</surname><given-names>J</given-names></name><name><surname>Schumacher</surname><given-names>M</given-names></name><name><surname>Herrmann-Lingen</surname><given-names>C</given-names></name></person-group>
<year>2004</year>
<article-title>Depression as a risk factor for mortality in patients with
coronary heart disease: a meta-analysis.</article-title>
<source>Psychosomatic medicine</source>
<volume>Nov-Dec; 66(6)</volume>
<fpage>802</fpage>
<lpage>13</lpage>
</element-citation></ref><ref id="pone.0002350-Bremmer1"><label>7</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bremmer</surname><given-names>MA</given-names></name><name><surname>Hoogendijk</surname><given-names>WJ</given-names></name><name><surname>Deeg</surname><given-names>DJ</given-names></name><name><surname>Schoevers</surname><given-names>RA</given-names></name><name><surname>Schalk</surname><given-names>BW</given-names></name><name><surname>Beekman</surname><given-names>AT</given-names></name></person-group>
<year>2006</year>
<article-title>Depression in older age is a risk factor for first ischemic
cardiac events.</article-title>
<source>Am J Geriatr Psychiatry</source>
<volume>Jun; 14(6)</volume>
<fpage>523</fpage>
<lpage>30</lpage>
</element-citation></ref><ref id="pone.0002350-Rosengren1"><label>8</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rosengren</surname><given-names>A</given-names></name><name><surname>Hawken</surname><given-names>S</given-names></name><name><surname>Ounpuu</surname><given-names>S</given-names></name><etal/></person-group>
<year>2004</year>
<article-title>Association of psychosocial risk factors with risk of acute
myocardial infarction in 11119 cases and 13648 controls from 52 countries
(the INTERHEART study): case-control study.</article-title>
<source>Lancet</source>
<volume>364(9438)</volume>
<fpage>953</fpage>
<lpage>62</lpage>
<pub-id pub-id-type="pmid">15364186</pub-id></element-citation></ref><ref id="pone.0002350-Murray1"><label>9</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Murray</surname><given-names>CJ</given-names></name><name><surname>Lopez</surname><given-names>AD</given-names></name></person-group>
<year>1997</year>
<article-title>Alternative projections of mortality and disability by cause
1990&#x02013;2020: Global Burden of Disease Study.</article-title>
<source>Lancet</source>
<volume>May 24; 349(9064)</volume>
<fpage>1498</fpage>
<lpage>504</lpage>
</element-citation></ref><ref id="pone.0002350-Holmes1"><label>10</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Holmes</surname><given-names>SD</given-names></name><name><surname>Krantz</surname><given-names>DS</given-names></name><name><surname>Rogers</surname><given-names>H</given-names></name><name><surname>Gottdiener</surname><given-names>J</given-names></name><name><surname>Contrada</surname><given-names>RJ</given-names></name></person-group>
<year>2006</year>
<article-title>Mental stress and coronary artery disease: a multidisciplinary
guide.</article-title>
<source>Progress in cardiovascular disease</source>
<volume>49(2)</volume>
<fpage>106</fpage>
<lpage>122</lpage>
<pub-id pub-id-type="pmid">17046436</pub-id></element-citation></ref><ref id="pone.0002350-Patterson1"><label>11</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Patterson</surname><given-names>SM</given-names></name><name><surname>Krantz</surname><given-names>DS</given-names></name><name><surname>Gottdiener</surname><given-names>JS</given-names></name><name><surname>Hecht</surname><given-names>G</given-names></name><name><surname>Vargot</surname><given-names>S</given-names></name><name><surname>Goldstein</surname><given-names>DS</given-names></name></person-group>
<year>1995</year>
<article-title>Prothrombotic effects of environmental stress: changes in
platelet function, hematocrit, and total plasma protein.</article-title>
<source> Psychosomatic medicine</source>
<volume>Nov-Dec; 57(6)</volume>
<fpage>592</fpage>
<lpage>9</lpage>
</element-citation></ref><ref id="pone.0002350-Dintenfass1"><label>12</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dintenfass</surname><given-names>L</given-names></name><name><surname>Lake</surname><given-names>B</given-names></name></person-group>
<year>1977</year>
<article-title>Blood viscosity factors in evaluation of submaximal work output
and cardiac activity in patients with myocardial infarction and angina, and
in normals.</article-title>
<source>Bibliotheca anatomica</source>
<volume>(16 Pt 2)</volume>
<fpage>498</fpage>
<lpage>500</lpage>
</element-citation></ref><ref id="pone.0002350-Jan1"><label>13</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jan</surname><given-names>KM</given-names></name><name><surname>Chien</surname><given-names>S</given-names></name><name><surname>Bigger</surname><given-names>JT</given-names><suffix>Jr</suffix></name></person-group>
<year>1975</year>
<article-title>Observations on blood viscosity changes after acute myocardial
infarction.</article-title>
<source>Circulation</source>
<volume>Jun; 51(6)</volume>
<fpage>1079</fpage>
<lpage>84</lpage>
</element-citation></ref><ref id="pone.0002350-Lowe1"><label>14</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lowe</surname><given-names>GD</given-names></name></person-group>
<year>1986</year>
<article-title>Blood rheology in arterial disease.</article-title>
<source> Clin Sci (Lond)</source>
<volume>Aug; 71(2)</volume>
<fpage>137</fpage>
<lpage>46</lpage>
</element-citation></ref><ref id="pone.0002350-Burge1"><label>15</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Burge</surname><given-names>PS</given-names></name><name><surname>Johnson</surname><given-names>WS</given-names></name><name><surname>Prankerd</surname><given-names>TA</given-names></name></person-group>
<year>1975</year>
<article-title>Morbidity and mortality in pseudopolycythaemia.</article-title>
<source>Lancet</source>
<volume>Jun 7; 1(7919)</volume>
<fpage>1266</fpage>
<lpage>9</lpage>
</element-citation></ref><ref id="pone.0002350-Isbister1"><label>16</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Isbister</surname><given-names>JP</given-names></name></person-group>
<year>1987</year>
<article-title>The contracted plasma volume syndromes (relative polycythaemias)
and their haemorheological significance.</article-title>
<source>Bailliere's clinical haematology</source>
<volume>Sep; 1(3)</volume>
<fpage>665</fpage>
<lpage>93</lpage>
</element-citation></ref><ref id="pone.0002350-Sorlie1"><label>17</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sorlie</surname><given-names>PD</given-names></name><name><surname>Garcia-Palmieri</surname><given-names>MR</given-names></name><name><surname>Costas</surname><given-names>R</given-names><suffix>Jr</suffix></name><name><surname>Havlik</surname><given-names>RJ</given-names></name></person-group>
<year>1981</year>
<article-title>Hematocrit and risk of coronary heart disease: the Puerto Rico
Health Program.</article-title>
<source>American heart journal</source>
<volume>Apr; 101(4)</volume>
<fpage>456</fpage>
<lpage>61</lpage>
</element-citation></ref><ref id="pone.0002350-Allen1"><label>18</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Allen</surname><given-names>MT</given-names></name><name><surname>Patterson</surname><given-names>SM</given-names></name></person-group>
<year>1995</year>
<article-title>Hemoconcentration and stress: a review of physiological
mechanisms and relevance for cardiovascular disease risk.</article-title>
<source>Biol Psychol</source>
<volume>Aug; 41(1)</volume>
<fpage>1</fpage>
<lpage>27</lpage>
</element-citation></ref><ref id="pone.0002350-Maes1"><label>19</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Maes</surname><given-names>M</given-names></name><name><surname>Van der Planken</surname><given-names>M</given-names></name><name><surname>Van Gastel</surname><given-names>A</given-names></name><name><surname>Bruyland</surname><given-names>K</given-names></name><name><surname>Van Hunsel</surname><given-names>F</given-names></name><name><surname>Neels</surname><given-names>H</given-names></name><name><surname>Hendriks</surname><given-names>D</given-names></name><name><surname>Wauters</surname><given-names>A</given-names></name><name><surname>Demedts</surname><given-names>P</given-names></name><name><surname>Janca</surname><given-names>A</given-names></name><name><surname>Scharpe</surname><given-names>S</given-names></name></person-group>
<year>1998</year>
<article-title>Influence of academic examination stress on hematological
measurements in subjectively healthy volunteers.</article-title>
<source>Psychiatry Research</source>
<volume>80</volume>
<fpage>201</fpage>
<lpage>212</lpage>
<pub-id pub-id-type="pmid">9796936</pub-id></element-citation></ref><ref id="pone.0002350-Muldoon1"><label>20</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Muldoon</surname><given-names>MF</given-names></name><name><surname>Herbert</surname><given-names>TB</given-names></name><name><surname>Patterson</surname><given-names>SM</given-names></name><name><surname>Kameneva</surname><given-names>M</given-names></name><name><surname>Raible</surname><given-names>R</given-names></name><name><surname>Manuck</surname><given-names>SB</given-names></name></person-group>
<year>1995</year>
<article-title>Effects of acute psychological stress on serum lipid levels,
hemoconcentration, and blood viscosity.</article-title>
<source>Archives of internal medicine</source>
<volume>155</volume>
<fpage>615</fpage>
<lpage>620</lpage>
<pub-id pub-id-type="pmid">7887757</pub-id></element-citation></ref><ref id="pone.0002350-Muldoon2"><label>21</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Muldoon</surname><given-names>MF</given-names></name><name><surname>Bachen</surname><given-names>EA</given-names></name><name><surname>Manuck</surname><given-names>SB</given-names></name><name><surname>Waldstein</surname><given-names>SR</given-names></name><name><surname>Bricker</surname><given-names>PL</given-names></name><name><surname>Bennett</surname><given-names>JA</given-names></name></person-group>
<year>1992</year>
<article-title>Acute cholesterol responses to mental stress and change in
posture.</article-title>
<source>Archives of internal medicine</source>
<volume>152(4)</volume>
<fpage>775</fpage>
<lpage>80</lpage>
<pub-id pub-id-type="pmid">1558435</pub-id></element-citation></ref><ref id="pone.0002350-Patterson2"><label>22</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Patterson</surname><given-names>SM</given-names></name><name><surname>Matthews</surname><given-names>KA</given-names></name><name><surname>Allen</surname><given-names>MT</given-names></name><name><surname>Owens</surname><given-names>JF</given-names></name></person-group>
<year>1995</year>
<article-title>Stress-induced hemoconcentration of blood cells and lipids in
healthy women during acute psychological stress.</article-title>
<source>Health Psychol</source>
<volume>Jul; 14(4)</volume>
<fpage>319</fpage>
<lpage>24</lpage>
</element-citation></ref><ref id="pone.0002350-Wong1"><label>23</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wong</surname><given-names>ML</given-names></name><name><surname>Deloukas</surname><given-names>P</given-names></name><name><surname>Whittaker</surname><given-names>P</given-names></name><name><surname>Delgado</surname><given-names>M</given-names></name><name><surname>Cantor</surname><given-names>RM</given-names></name><name><surname>McCann</surname><given-names>SM</given-names></name><etal/></person-group>
<year>2006</year>
<article-title>Phosphodiesterase genes are associated with susceptibility to
major depression and antidepressant treatment response.</article-title>
<source>Proceedings of the National Academy of Sciences of the United States of
America Oct 10</source>
<volume>103(41)</volume>
<fpage>15124</fpage>
<lpage>15129</lpage>
</element-citation></ref><ref id="pone.0002350-Hamilton1"><label>24</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hamilton</surname><given-names>M</given-names></name></person-group>
<year>1960</year>
<article-title>A rating scale for depression.</article-title>
<source>Journal of neurology, neurosurgery, and psychiatry</source>
<volume>Feb; 23</volume>
<fpage>56</fpage>
<lpage>62</lpage>
</element-citation></ref><ref id="pone.0002350-Licinio1"><label>25</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Licinio</surname><given-names>J</given-names></name><name><surname>O'Kirwan</surname><given-names>F</given-names></name><name><surname>Irizarry</surname><given-names>K</given-names></name><name><surname>Merriman</surname><given-names>B</given-names></name><name><surname>Thakur</surname><given-names>S</given-names></name><name><surname>Jepson</surname><given-names>R</given-names></name><etal/></person-group>
<year>2004</year>
<article-title>Association of a corticotropin-releasing hormone receptor 1
haplotype and antidepressant treatment response in Mexican-Americans.</article-title>
<source>Molecular psychiatry</source>
<volume>Dec; 9(12)</volume>
<fpage>1075</fpage>
<lpage>82</lpage>
</element-citation></ref><ref id="pone.0002350-deSimone1"><label>26</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>de Simone</surname><given-names>G</given-names></name><name><surname>Devereux</surname><given-names>RB</given-names></name><name><surname>Chien</surname><given-names>S</given-names></name><name><surname>Alderman</surname><given-names>MH</given-names></name><name><surname>Atlas</surname><given-names>SA</given-names></name><name><surname>Laragh</surname><given-names>JH</given-names></name></person-group>
<year>1990</year>
<article-title>Relation of blood viscosity to demographic and physiologic
variables and to cardiovascular risk factors in apparently normal adults.</article-title>
<source>Circulation</source>
<volume>Jan; 81(1)</volume>
<fpage>107</fpage>
<lpage>17</lpage>
</element-citation></ref><ref id="pone.0002350-Dill1"><label>27</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dill</surname><given-names>DB</given-names></name><name><surname>Costill</surname><given-names>DL</given-names></name></person-group>
<year>1974</year>
<article-title>Calculation of percentage changes in volumes of blood, plasma,
and red cells in dehydration.</article-title>
<source>J Appl Physiol</source>
<volume>Aug; 37(2)</volume>
<fpage>247</fpage>
<lpage>8</lpage>
</element-citation></ref><ref id="pone.0002350-Gold1"><label>28</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gold</surname><given-names>PW</given-names></name><name><surname>Wong</surname><given-names>ML</given-names></name><name><surname>Goldstein</surname><given-names>DS</given-names></name><name><surname>Gold</surname><given-names>HK</given-names></name><name><surname>Ronsaville</surname><given-names>DS</given-names></name><name><surname>Esler</surname><given-names>M</given-names></name><etal/></person-group>
<year>2005</year>
<article-title>Cardiac implications of increased arterial entry and reversible
24-h central and peripheral norepinephrine levels in melancholia.</article-title>
<source>Proceedings of the National Academy of Sciences of the United States of
America</source>
<volume>Jun 7; 102(23)</volume>
<fpage>8303</fpage>
<lpage>8</lpage>
</element-citation></ref><ref id="pone.0002350-VanHunsel1"><label>29</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Van Hunsel</surname><given-names>F</given-names></name><name><surname>Wauters</surname><given-names>A</given-names></name><name><surname>Vandoolaeghe</surname><given-names>E</given-names></name><name><surname>Neels</surname><given-names>H</given-names></name><name><surname>Demedts</surname><given-names>P</given-names></name><name><surname>Maes</surname><given-names>M</given-names></name></person-group>
<year>1996</year>
<article-title>Lower total serum protein, albumin, and beta- and gamma-globulin
in major and treatment-resistant depression: effects of antidepressant
treatments.</article-title>
<source>Psychiatry research</source>
<volume>Dec 20; 65(3)</volume>
<fpage>159</fpage>
<lpage>69</lpage>
</element-citation></ref><ref id="pone.0002350-Huang1"><label>30</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Huang</surname><given-names>TL</given-names></name></person-group>
<year>2002</year>
<article-title>Lower serum albumin levels in patients with mood disorders.</article-title>
<source>Chang Gung medical journal</source>
<volume>Aug; 25(8)</volume>
<fpage>509</fpage>
<lpage>13</lpage>
</element-citation></ref><ref id="pone.0002350-Maes2"><label>31</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Maes</surname><given-names>M</given-names></name><name><surname>Van de Vyvere</surname><given-names>J</given-names></name><name><surname>Vandoolaeghe</surname><given-names>E</given-names></name><name><surname>Bril</surname><given-names>T</given-names></name><name><surname>Demedts</surname><given-names>P</given-names></name><name><surname>Wauters</surname><given-names>A</given-names></name><etal/></person-group>
<year>1996</year>
<article-title>Alterations in iron metabolism and the erythron in major
depression: further evidence for a chronic inflammatory process.</article-title>
<source>Journal of affective disorders</source>
<volume>Sep 9; 40(1&#x02013;2)</volume>
<fpage>23</fpage>
<lpage>33</lpage>
</element-citation></ref><ref id="pone.0002350-Ahrens1"><label>32</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ahrens</surname><given-names>B</given-names></name><name><surname>Muller-Oerlinghausen</surname><given-names>B</given-names></name><name><surname>Schou</surname><given-names>M</given-names></name><name><surname>Wolf</surname><given-names>T</given-names></name><name><surname>Alda</surname><given-names>M</given-names></name><name><surname>Grof</surname><given-names>E</given-names></name><etal/></person-group>
<year>1995</year>
<article-title>Excess cardiovascular and suicide mortality of affective
disorders may be reduced by lithium prophylaxis.</article-title>
<source>Journal of affective disorders</source>
<volume>Feb 21; 33(2)</volume>
<fpage>67</fpage>
<lpage>75</lpage>
</element-citation></ref><ref id="pone.0002350-Avery1"><label>33</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Avery</surname><given-names>D</given-names></name><name><surname>Winokur</surname><given-names>G</given-names></name></person-group>
<year>1976</year>
<article-title>Mortality in depressed patients treated with electroconvulsive
therapy and antidepressants.</article-title>
<source>Archives of general psychiatry</source>
<volume>Sep; 33(9)</volume>
<fpage>1029</fpage>
<lpage>37</lpage>
</element-citation></ref><ref id="pone.0002350-Cohen1"><label>34</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cohen</surname><given-names>HW</given-names></name><name><surname>Gibson</surname><given-names>G</given-names></name><name><surname>Alderman</surname><given-names>MH</given-names></name></person-group>
<year>2000</year>
<article-title>Excess risk of myocardial infarction in patients treated with
antidepressant medications: association with use of tricyclic agents.</article-title>
<source>The American journal of medicine</source>
<volume>Jan; 108(1)</volume>
<fpage>2</fpage>
<lpage>8</lpage>
</element-citation></ref><ref id="pone.0002350-Roose1"><label>35</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Roose</surname><given-names>SP</given-names></name><name><surname>Laghrissi-Thode</surname><given-names>F</given-names></name><name><surname>Kennedy</surname><given-names>JS</given-names></name><name><surname>Nelson</surname><given-names>JC</given-names></name><name><surname>Bigger</surname><given-names>JT</given-names><suffix>Jr</suffix></name><name><surname>Pollock</surname><given-names>BG</given-names></name><etal/></person-group>
<year>1998</year>
<article-title>Comparison of paroxetine and nortriptyline in depressed patients
with ischemic heart disease.</article-title>
<source>Jama</source>
<volume>Jan 28; 279(4)</volume>
<fpage>287</fpage>
<lpage>91</lpage>
</element-citation></ref><ref id="pone.0002350-Glassman1"><label>36</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Glassman</surname><given-names>AH</given-names></name><name><surname>O'Connor</surname><given-names>CM</given-names></name><name><surname>Califf</surname><given-names>RM</given-names></name><name><surname>Swedberg</surname><given-names>K</given-names></name><name><surname>Schwartz</surname><given-names>P</given-names></name><name><surname>Bigger</surname><given-names>JT</given-names><suffix>Jr</suffix></name><etal/></person-group>
<year>2002</year>
<article-title>Sertraline treatment of major depression in patients with acute
MI or unstable angina.</article-title>
<source>Jama</source>
<volume>Aug 14; 288(6)</volume>
<fpage>701</fpage>
<lpage>9</lpage>
</element-citation></ref><ref id="pone.0002350-Taylor1"><label>37</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Taylor</surname><given-names>CB</given-names></name><name><surname>Youngblood</surname><given-names>ME</given-names></name><name><surname>Catellier</surname><given-names>D</given-names></name><name><surname>Veith</surname><given-names>RC</given-names></name><name><surname>Carney</surname><given-names>RM</given-names></name><name><surname>Burg</surname><given-names>MM</given-names></name><etal/></person-group>
<year>2005</year>
<article-title>Effects of antidepressant medication on morbidity and mortality
in depressed patients after myocardial infarction.</article-title>
<source>Archives of general psychiatry</source>
<volume>Jul; 62(7)</volume>
<fpage>792</fpage>
<lpage>8</lpage>
</element-citation></ref><ref id="pone.0002350-Gehi1"><label>38</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gehi</surname><given-names>A</given-names></name><name><surname>Haas</surname><given-names>D</given-names></name><name><surname>Pipkin</surname><given-names>S</given-names></name><name><surname>Whooley</surname><given-names>MA</given-names></name></person-group>
<year>2005</year>
<article-title>Depression and medication adherence in outpatients with coronary
heart disease: findings from the Heart and Soul Study.</article-title>
<source>Archives of internal medicine</source>
<volume>Nov 28; 165(21)</volume>
<fpage>2508</fpage>
<lpage>13</lpage>
</element-citation></ref></ref-list></back></article>